|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:advocacy
|
required for participation
|
|
gptkbp:biological_mechanism
|
m RNA encoding for antigen
|
|
gptkbp:clinical_trial
|
gptkb:2020
gptkb:Bio_NTech
Phase 1
pending
various sites globally
overall survival
open-label study
NCT number assigned
|
|
gptkbp:clinical_trial_phase_description
|
Phase 1 trial for safety
|
|
gptkbp:clinical_trial_results_publication
|
expected after completion
|
|
gptkbp:collaboration
|
gptkb:Pfizer
|
|
gptkbp:collaborations
|
academic institutions
with other biotech firms
|
|
gptkbp:committee
|
established for oversight
|
|
gptkbp:developed_by
|
gptkb:Bio_NTech
|
|
gptkbp:dosage_form
|
determined in trials
|
|
gptkbp:eligibility
|
ongoing
|
|
gptkbp:feedback
|
collected during trials
|
|
gptkbp:formulation
|
lipid nanoparticles
|
|
gptkbp:funding
|
secured from investors
|
|
gptkbp:future_prospects
|
planned for additional indications
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bio NTech's BNT111
|
|
gptkbp:immune_response_type
|
T-cell response
|
|
gptkbp:impact
|
potential to change cancer treatment paradigm
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:investigates
|
active
|
|
gptkbp:investigator_initiated_trials
|
may occur
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:is_monitored_by
|
conducted throughout study
|
|
gptkbp:is_tested_for
|
immune response markers
|
|
gptkbp:mechanism_of_action
|
stimulates immune response
|
|
gptkbp:objective
|
evaluate safety and efficacy
|
|
gptkbp:part_of
|
BNT series
|
|
gptkbp:partnership
|
with regulatory agencies
|
|
gptkbp:patient_population
|
adult patients
|
|
gptkbp:project
|
early clinical development
|
|
gptkbp:publication
|
published in scientific journals
|
|
gptkbp:regulatory_compliance
|
not yet approved
|
|
gptkbp:related_products
|
filed with FDA
|
|
gptkbp:research
|
completed
|
|
gptkbp:research_areas
|
gptkb:immunotherapy
oncology
|
|
gptkbp:research_ethics_approval
|
obtained prior to trials
|
|
gptkbp:research_focus
|
personalized cancer therapy
|
|
gptkbp:route_of_administration
|
injection
intratumoral
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:scientific_goals
|
improve treatment outcomes
|
|
gptkbp:service_frequency
|
multiple doses
|
|
gptkbp:side_effect
|
monitored during trials
|
|
gptkbp:sponsor
|
gptkb:Bio_NTech_SE
|
|
gptkbp:status
|
in development
|
|
gptkbp:target_patient_group
|
patients with advanced melanoma
|
|
gptkbp:targets
|
gptkb:NY-ESO-1
gptkb:Oncology
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:bfsParent
|
gptkb:m_RNA_cancer_vaccine
|
|
gptkbp:bfsLayer
|
6
|